Angioedema Caused by Carbamazepine or Acetazolamide: A Single Drug Solution - An illustrative Case Report
DOI:
https://doi.org/10.17140/NOJ-1-105Keywords:
Angioedema; Carbamazepine; Acetazolamide; TopiramateAbstract
We report a rare case of angioedema in an adolescent female with multiple problems,
seizures migraines, peudotumor cerebrii, supraventricular tachycardia, and obesity. Management of drug therapy in such patients presents a clinical challenge. We discuss a single drug
solution particularly in those patients in whom the memory of side effects of the drug is a vivid
reality.
References
Syn WK, Naisbitt DJ, Holt AP, Pirmohamed M, Mutimer DJ. Carbamazepine-induced acute liver failure as part of DRESS syndrome. Int J Pract. 2005; 59: 988-991. doi: 10.1111/j.1368- 5031.2005.00550.x
Kristinsson A. Fatal reaction to acetazolamide. Br J Oph-thalmol. 1967; 51(5): 348-349.
Fischer M, Hamm H, Wirbelauer J. [Severe drug-related skin reaction: toxic epidermal necrolysis caused by carbam-azepine] Klin Padiatr. 2004; 216(5): 288-293. doi: 10.1055/s-2004-44896
Cohen EG, Soliman AM. Changing trends in angioedema. Ann Otol Rhinol Laryngol. 2001; 110(8): 701-706.
Elias A, Madhusoodanan S, Pudukkadan D, Antony JT. Angioedema and maculopapular eruptions associated with carbamazepine administration. CNS Spectr. 2006; 11(5): 352- 354.
Stock JG. Sulfonamide hypersensitivity and acetazol-amide. Arch Opthalmol. 1990; 108: 634-635. doi: 10.1001/ archopht.1990.01070070020005
Duran-Ferreras E, Mir-Mercader J, Morales-Martinez MD, Martinez-Parra C. Anticonvulsant hypersensitivity syndrome with severe repercussions in the skin and kidneys due to Car-bamazepine. Rev Neurol. 2004; 38(12): 1136-1138.
Middleton E Jr, Reed CE, Ellis EF. Allergy: Principles and practice. 6th Eds. St Louis, MO, USA: Mosby-Year Book Inc; 2002; 2: 1537-558.
Bourgeois BF. Drug interaction profile of topiramate. Epi-lepsia. 1996; 37Suppl(2): S14-S17. Neuro Open J
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Neuro (NEURO) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.